

This Issue's Contributors



Gail M. Wilkes, MS, RNC, AOCN®, author of “Therapeutic Options in the Management of Colon Cancer: 2005 Update” (p. 31), is an oncology nurse educator and nurse practitioner at Boston Medical Center in Massachusetts. As a nurse practitioner, Wilkes has worked in gastrointestinal oncology and has been impressed by the chemotherapeutic advances made in the adjuvant and metastatic treatment of colon cancer. She wrote the article as an update to a 2002 *Clinical*

Journal of Oncology Nursing article that described advances relating to oxaliplatin and infusional 5-fluorouracil and leucovorin.

Nancy J. Washburn, MSN, APRN, BC, ANP, AOCN®, NP, OCN®, primary author of “Outpatient Genetic Risk Assessment in Women With Breast Cancer: One Center’s Experience” (p. 49), is an oncology nurse practitioner at the Kansas City Cancer Center (KCCC) South in Missouri. In addition to teaching and seeing patients, she has always been interested in genetics and was chosen to attend an Oncology Nursing Society Genetics Short Course in 2003. According to Washburn, “The literature has shown the importance of incorporating genetics programs into practice, but not how to do it in a community-based setting.” Therefore, she attempted to “show one way to identify individuals at high risk for genetic mutation and to make changes in practice that will help manage the patients’ risk of developing cancer or assist in risk reduction for their family members.” Coauthors Valerie K. Sommer, RN, MSN, FNP-C, is an oncology nurse practitioner at KCCC East in Lee’s Summit, MO; Sarah E. Spencer, RN, BSN, CCRC, OCN®, BA, is a research RN at KCCC Southwest in Overland Park, KS; Sandra K. Simmons, RN, MSN, ARNP-C, AOCN®, is an oncology nurse practitioner at KCCC West in Missouri; Barbara W. Adkins, BSN, MSN, ARNP-C, AOCN®, is a nurse practitioner at KCCC Southwest; Mary R. Rogers, RN, CS, FNP, is a nurse practitioner at KCCC East; Patty L. Gerken, MSN, ANP, OCN®, AOCN®, is a nurse practitioner at KCCC South; and Christina M. Bromley, BS, MS, PhD, is the president of BioStat Solutions in Mt. Airy, MD.



Paula J. Franson, RN, MS, AOCN®, primary author of “Antivascular Endothelial Growth Factor Monoclonal Antibody Therapy: A Promising Paradigm in Colorectal Cancer” (p. 55), is a hematology medical science liaison for Genentech, Inc., in San Francisco, CA. At the time the article was written, she was a clinical research nurse at Rush University Medical Center in Chicago, IL, where she had firsthand experience with new targeted agents,

including antivascular endothelial growth factor. According to Franson, “New agents such as bevacizumab are promising additions to our anticancer weaponry, highlighting a more powerful trend—the targeting of the molecular mechanism underlying the disease process—that will maximize outcomes and quality of life for patients with cancer.” Coauthor Denise V. Lapka, RN, MS, AOCN®, CCNS, is an oncology clinical

coordinator at Genentech BioOncology in South San Francisco, CA. At the time the article was written, Lapka was a research coordinator in the Clinical Trials Department at Ingalls Hospital in Harvey, IL.



Bridget A. Cahill, RN, APN, MS, author of “Management of Patients Who Have Undergone Hepatic Artery Chemoembolization” (p. 69), is a certified adult nurse practitioner in the gastrointestinal program in the Department of Medicine, Division of Hematology/Oncology, at Northwestern Medical Faculty Foundation in Chicago, IL.

In her current position, she manages patients who have undergone hepatic artery chemoembolization. According to Cahill, “Very little information is available to oncology nurses on hepatocellular carcinoma and hepatic artery embolization. I believe it is important for oncology nurses to understand the procedure, side effects, and management in order to serve our patients.”



Pamela Hallquist Viale, RN, MS, CS, ANP, OCN®, author of “Integrating Aprepitant and Palonosetron Into Clinical Practice: A Role for the New Antiemetics” (p. 77), is an oncology nurse practitioner at the Santa Clara Valley Medical Center in San Jose, CA, and an assistant clinical professor in the Department of Physiological Nursing at the University of California, San Francisco. She is interested in symptom management in patients with cancer and has lectured on

chemotherapy-induced nausea and vomiting (CINV) across the United States. With new antiemetics to help combat CINV, Viale is committed to educating oncology nurses about advances in CINV management.

Maribeth Hohenstein, RN, BSN, OCN®, CCRC®, author of “Patient-Specific Vaccine Therapy for Non-Hodgkin Lymphoma” (p. 85), is a research nurse coordinator in the Section of Hematology and Oncology at the University of Nebraska Medical Center in Omaha, where she coordinates care and manages protocols with investigational drugs for patients with lymphoma. Because of her position as a research nurse, she has had the opportunity to work with many different novel therapies for lymphoma. “Vaccines for lymphoma are fascinating and one of the more encouraging new therapies I’ve worked with,” she said. “Targeted therapies have provided safe and effective treatment options for our patients.” Coauthors Susan E. King, RN, MS, OCN®, is medical science liaison at Genitope Corporation in Redwood City, CA; Jennifer M. Fiore, RN, MA, ANP-C, is a nurse practitioner with the Division of Hematology and Medical Oncology in Weill Medical College at Cornell University in New York, NY; Teresa O’Brien, RN, BSN, OCN®, is coordinator of research nurses in the Section of Hematology/Oncology at Rush University Medical Center in Chicago, IL; and Susan Blumel, RN, BSN, OCN®, CCRC®, is a clinical research nurse coordinator in the Section of Hematology and Oncology at the University of Nebraska Medical Center.